Pharmacologically-induced metabolic acidosis: A review

Drug Safety

Volumn 33, Issue 5, 2010, Pages 371-391

  Liamis, George ^a   Milionis, Haralampos J ^a   Elisaf, Moses ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ACETAZOLAMIDE; AMILORIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CIDOFOVIR; COTRIMOXAZOLE; CYCLOSPORIN; DIDANOSINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETHYLENE GLYCOL; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IFOSFAMIDE; ISONIAZID; KETOCONAZOLE; LINEZOLID; NALIDIXIC ACID; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PENTAMIDINE; PROPOFOL; RENIN INHIBITOR; SALICYLIC ACID; SEVELAMER; SPIRONOLACTONE; TACROLIMUS; TENOFOVIR; TRIAMTERENE; UNINDEXED DRUG;

ACIDITY; ANION GAP; ARTERIAL GAS; DIABETIC KETOACIDOSIS; FANCONI RENOTUBULAR SYNDROME; GLAUCOMA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERALIMENTATION; HYPERKALEMIA; HYPOALDOSTERONISM; KETOACIDOSIS; KIDNEY FAILURE; KIDNEY TUBULE ACIDOSIS; LACTIC ACIDOSIS; METABOLIC ACIDOSIS; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTON TRANSPORT; REVIEW; RHABDOMYOLYSIS;

ACID-BASE EQUILIBRIUM; ACIDOSIS; ACIDOSIS, LACTIC; ACIDOSIS, RENAL TUBULAR; BICARBONATES; DIABETIC KETOACIDOSIS; HUMANS;

EID: 77951122425     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11533790-000000000-00000     Document Type: Review

References (188)

1. Adrogue HJ. Metabolic acidosis: pathophysiology, diag-nosis and management. J Nephrol 2006 Mar-Apr; 19 Suppl. 9: S62-9
2. Mitch WE. Metabolic and clinical consequences of metabolic acidosis. J Nephrol 2006 Mar-Apr; 19 Suppl. 9: S70-5
3. Kreisberg RA, Wood BC. Drug and chemical-induced metabolic acidosis. Clin Endocrinol Metab 1983 Jul; 12 (2): 391-411
4. Gabow PA. Disorders associated with an altered anion gap. Kidney Int 1985 Feb; 27 (2): 472-483
5. Feldman M, Soni N, Dickson B. Influence of hypoalbuminemia or hyperalbuminemia on the serum anion gap. J Lab Clin Med 2005 Dec; 146 (6): 317-320
6. Figge J, Jabor A, Kazda A, et al. Anion gap and hypoalbuminemia. Crit Care Med 1998 Nov; 26 (11): 1807-1810
7. Kraut JA, Kurtz I. Metabolic acidosis of CKD: diagnosis, clinical characteristics, and treatment. Am J Kidney Dis 2005 Jun; 45 (6): 978-993
8. Bailey JL. Metabolic acidosis: an unrecognized cause of morbidity in the patient with chronic kidney disease. Kidney Int Suppl 2005 Jul; (96): S15-23
9. Gabow PA, Kaehny WD, Fennessey PV, et al. Diagnostic importance of an increased serum anion gap. N Engl J Med 1980 Oct 9; 303 (15): 854-858
10. Wang F, Butler T, Rabbani GH, et al. The acidosis of cholera: contributions of hyperproteinemia, lactic acidemia, and hyperphosphatemia to an increased serum anion gap. N Engl J Med 1986 Dec 18; 315 (25): 1591-1595
11. Iberti TJ, Leibowitz AB, Papadakos PJ, et al. Low sensitivity of the anion gap as a screen to detect hyperlactate-mia in critically ill patients. Crit Care Med 1990 Mar; 18 (3): 275-277
12. Emmett M. Anion-gap interpretation: the old and the new. Nat Clin Pract Nephrol 2006 Jan; 2 (1): 4-5
13. Goodkin DA, Krishna GG, Narins RG. The role of the anion gap in detecting and managing mixed metabolic acid-base disorders. Clin Endocrinol Metab 1984 Jul; 13 (2): 333-349
14. Reddy P, Mooradian AD. Clinical utility of anion gap in deciphering acid-base disorders. Int J Clin Pract 2009 Oct; 63 (10): 1516-1525
15. Corey HE. Stewart and beyond: new models of acid-base balance. Kidney Int 2003 Sep; 64 (3): 777-787
16. Moviat M, van Haren F, van der Hoeven H. Conventional or physicochemical approach in intensive care unit patients with metabolic acidosis. Crit Care 2003 Jun; 7 (3): R41-5
17. Martin M, Murray J, Berne T, et al. Diagnosis of acid-base derangements and mortality prediction in the trauma intensive care unit: the physiochemical approach. J Trauma 2005 Feb; 58 (2): 238-243
18. Boniatti MM, Cardoso PR, Castilho RK, et al. Acid-base disorders evaluation in critically ill patients: we can im-prove our diagnostic ability. Intensive Care Med 2009 Aug; 35 (8): 1377-1382
19. Dubin A, Menises MM, Masevicius FD, et al. Comparison of three different methods of evaluation of metabolic acid-base disorders. Crit Care Med 2007 May; 35 (5): 1264-1270 (Pubitemid 46642652)
20. Sebastian A, Schambelan M, Lindenfeld S, et al. Amelioration of metabolic acidosis with fludrocortisone ther-apy in hyporeninemic hypoaldosteronism. N Engl J Med 1977 Sep 15; 297 (11): 576-583
21. Szylman P, Better OS, Chaimowitz C, et al. Role of hyperkalemia in the metabolic acidosis of isolated hypoaldos-teronism. N Engl J Med 1976 Feb 12; 294 (7): 361-365
22. Jaeger P, Bonjour JP, Karlmark B, et al. Influence of acute potassium loading on renal phosphate transport in the rat kidney. Am J Physiol 1983 Nov; 245 (5 Pt 1): F601-5
23. Holubek W, Stolbach A, Nurok S, et al. A report of two deaths from massive ibuprofen ingestion. J Med Toxicol 2007 Jun; 3 (2): 52-55
24. Sakemi T, Ohchi N, Sanai T, et al. Captopril-induced metabolic acidosis with hyperkalemia. Am J Nephrol 1988; 8 (3): 245-248
25. Henger A, Tutt P, Riesen WF, et al. Acid-base and endocrine effects of aldosterone and angiotensin II inhibition in metabolic acidosis in human patients. J Lab Clin Med 2000 Nov; 136 (5): 379-389
26. Naka T, Egi M, Bellomo R, et al. Low-dose citrate continuous veno-venous hemofiltration (CVVH) and acid-base balance. Int J Artif Organs 2005 Mar; 28 (3): 222-228 (Pubitemid 40667610)
27. Gabow PA, Moore S, Schrier RW. Spironolactoneinduced hyperchloremic acidosis in cirrhosis. Ann Intern Med 1979 Mar; 90 (3): 338-340
28. Reyes AJ, Leary WP, Crippa G, et al. The aldosterone antagonist and facultative diuretic eplerenone: a critical review. Eur J Intern Med 2005 Feb; 16 (1): 3-11
29. DuBose Jr TD. Molecular and pathophysiologic mechanisms of hyperkalemic metabolic acidosis. Trans Am Clin Climatol Assoc 2000; 111: 122-33, discussion 133-134
30. Heering P, Ivens K, Aker S, et al. Distal tubular acidosis induced by FK506. Clin Transplant 1998 Oct; 12 (5): 465-471
31. Yakupoglu HY, Corsenca A, Wahl P, et al. Posttransplant acidosis and associated disorders of mineral metabolism in patients with a renal graft. Transplantation 2007 Nov 15; 84 (9): 1151-1157
32. Jick H.Adverse reactions totrimethoprim-sulfamethoxazole in hospitalized patients. Rev Infect Dis 1982 Mar-Apr; 4 (2): 426-428
33. Venzin RM, Cohen CD, Maggiorini M, et al. Aliskirenassociated acute renal failure with hyperkalemia. Clin Nephrol 2009 Mar; 71 (3): 326-328
34. Alappan R, Perazella MA, Buller GK. Hyperkalemia in hospitalized patients treated with trimethoprim-sulfa-methoxazole. Ann Intern Med 1996 Feb 1; 124 (3): 316-320
35. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999 Mar 11; 340 (10): 764-771
36. Douglas JB, Healy JK. Nephrotoxic effects of amphotericin B, including renal tubular acidosis. Am J Med 1969 Jan; 46 (1): 154-162
37. Gil FZ, Malnic G. Effect of amphotericin B on renal tubular acidification in the rat. Pflugers Arch 1989 Jan; 413 (3): 280-286
38. Stamm AM, Diasio RB, Dismukes WE, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987 Aug; 83 (2): 236-242
39. Bedford JJ, Weggery S, Ellis G, et al. Lithium-induced nephrogenic diabetes insipidus: renal effects of amiloride. Clin J Am Soc Nephrol 2008 Sep; 3 (5): 1324-1331
40. Grunfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009 May; 5 (5): 270-276
41. Boton R, Gaviria M, Batlle DC. Prevalence, pathogenesis, and treatment of renal dysfunction associated with chronic lithium therapy. Am J Kidney Dis 1987 Nov; 10 (5): 329-345
42. Vigeral P, Kanfer A, Kenouch S, et al. Nephrogenic diabetes insipidus and distal tubular acidosis in methicillin-induced interstitial nephritis. Adv Exp Med Biol 1987; 212: 129-134
43. Navarro JF, Quereda C, Gallego N, et al. Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis 1996 Mar; 27 (3): 431-434
44. Gladden LB. A lactatic perspective on metabolism. Med Sci Sports Exerc 2008 Mar; 40 (3): 477-485
45. Kreisberg RA. Lactate homeostasis and lactic acidosis. Ann Intern Med 1980 Feb; 92 (2 Pt 1): 227-237
46. Madias NE. Lactic acidosis. Kidney Int 1986 Mar; 29 (3): 752-774
47. Arieff AI, Park R, Leach WJ, et al. Pathophysiology of experimental lactic acidosis in dogs. Am J Physiol 1980 Aug; 239 (2): F135-42
48. Arieff AI, Graf H. Pathophysiology of type A hypoxic lactic acidosis in dogs. Am J Physiol 1987 Sep; 253 (3 Pt 1): E271-6
49. Fimognari FL, Pastorelli R, Incalzi RA. Phenformininduced lactic acidosis in an older diabetic patient: a re-current drama (phenformin and lactic acidosis). Diabetes Care 2006 Apr; 29 (4): 950-951
50. Strack T. Metformin: a review. Drugs Today (Barc) 2008 Apr; 44 (4): 303-314
51. Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 2000 Jun 15; 348 Pt 3: 607-614
52. Dykens JA, Jamieson J, Marroquin L, et al. Biguanideinduced mitochondrial dysfunction yields increased lac-tate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol 2008 Dec 1; 233 (2): 203-210
53. Peters N, Jay N, Barraud D, et al. Metformin-associated lactic acidosis in an intensive care unit. Crit Care 2008; 12 (6): R149
54. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996 Feb 29; 334 (9): 574-579
55. Hong YC, O'Boyle CP, Chen IC, et al. Metforminassociated lactic acidosis in a pregnant patient. Gynecol Obstet Invest 2008; 66 (2): 138-141
56. Salpeter S, Greyber E, Pasternak G, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006; (1): CD002967
57. Bruijstens LA, van Luin M, Buscher-Jungerhans PM, et al. Reality of severe metformin-induced lactic acidosis in the absence of chronic renal impairment. Neth J Med 2008 May; 66 (5): 185-190
58. Nyirenda MJ, Sandeep T, Grant I, et al. Severe acidosis in patients taking metformin: rapid reversal and survival despite high APACHE score. Diabet Med 2006 Apr; 23 (4): 432-435
59. Audia P, Feinfeld DA, Dubrow A, et al. Metformin-induced lactic acidosis and acute pancreatitis precipitated by di-uretic, celecoxib, and candesartan-associated acute kidney dysfunction. Clin Toxicol (Phila) 2008 Feb; 46 (2): 164-166
60. Di Grande A, Vancheri F, Giustolisi V, et al. Metformininduced lactic acidosis in a type 2 diabetic patient with acute renal failure. Clin Ter 2008 Mar-Apr; 159 (2): 87-89
61. El-Hennawy AS, Jacob S, Mahmood AK. Metforminassociated lactic acidosis precipitated by diarrhea. Am J Ther 2007 Jul-Aug; 14 (4): 403-405
62. Silvestre J, Carvalho S, Mendes V, et al. Metformininduced lactic acidosis: a case series. J Med Case Reports 2007; 1: 126
63. Arenas-Pinto A, Grant AD, Edwards S, et al. Lactic acidosis in HIV infected patients: a systematic review of published cases. Sex Transm Infect 2003 Aug; 79 (4): 340-343
64. Falco V, Rodriguez D, Ribera E, et al. Severe nucleosideassociated lactic acidosis in human immunodeficiency virus-infected patients: report of 12 cases and review of the literature. Clin Infect Dis 2002 Mar 15; 34 (6): 838-846
65. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002 Mar 14; 346 (11): 811-820
66. Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002 Mar; 46 (3): 716-723 (Pubitemid 34157656)
67. Moyle GJ, Datta D, Mandalia S, et al. Hyperlactataemia and lactic acidosis during antiretroviral therapy: re-levance, reproducibility and possible risk factors. AIDS 2002 Jul 5; 16 (10): 1341-1349
68. Bonnet F, Bonarek M, Morlat P, et al. Risk factors for lactic acidosis in HIV-infected patients treated with nu-cleoside reverse-transcriptase inhibitors: a case-control study. Clin Infect Dis 2003 May 15; 36 (10): 1324-1328
69. Izzedine H, Launay-Vacher V, Deray G. Antiviral druginduced nephrotoxicity. Am J Kidney Dis 2005 May; 45 (5): 804-817
70. Nelson M, Azwa A, Sokwala A, et al. Fanconi syndrome and lactic acidosis associated with stavudine and lamivu-dine therapy. AIDS 2008 Jul 11; 22 (11): 1374-1376
71. Brickner SJ, Barbachyn MR, Hutchinson DK, et al. Linezolid (ZYVOX), the first member of a completely new class of antibacterial agents for treatment of serious gram-positive infections. J Med Chem 2008 Apr 10; 51 (7): 1981-1990
72. Wiener M, Guo Y, Patel G, et al. Lactic acidosis after treatment with linezolid. Infection 2007 Jun; 35 (4): 278-281
73. Carson J, Cerda J, Chae JH, et al. Severe lactic acidosis associated with linezolid use in a patient with the mi-tochondrial DNA A2706G polymorphism. Pharmaco-therapy 2007 May; 27 (5): 771-774
74. Palenzuela L, Hahn NM, Nelson Jr RP, et al. Does linezolid cause lactic acidosis by inhibiting mitochondrial protein synthesis? Clin Infect Dis 2005 Jun 15; 40 (12): e113-6
75. von der Lippe B, Sandven P, Brubakk O. Efficacy and safety of linezolid in multidrug resistant tuberculosis (MDR-TB): a report of ten cases. J Infect 2006 Feb; 52 (2): 92-96
76. Scotton P, Fuser R, Torresan S, et al. Early linezolidassociated lactic acidosis in a patient treated for tubercu-lous spondylodiscitis. Infection 2008 Aug; 36 (4): 387-388
77. Pea F, Scudeller L, Lugano M, et al. Hyperlactacidemia potentially due to linezolid overexposure in a liver trans-plant recipient. Clin Infect Dis 2006 Feb 1; 42 (3): 434-435
78. Chin L, Sievers ML, Herrier RN, et al. Convulsions as the etiology of lactic acidosis in acute isoniazid toxicity in dogs. Toxicol Appl Pharmacol 1979 Jun 30; 49 (2): 377-384
79. Alvarez FG, Guntupalli KK. Isoniazid overdose: four case reports and review of the literature. Intensive Care Med 1995 Aug; 21 (8): 641-644
80. Kalaci A, Duru M, Karazincir S, et al. Thoracic spine compression fracture during isoniazid-induced seizures: case report. Pediatr Emerg Care 2008 Dec; 24 (12): 842-844
81. Romero JA, Kuczler Jr FJ. Isoniazid overdose: recognition and management. Am Fam Physician 1998 Feb 15; 57 (4): 749-752
82. Al-Khafaji AH, Dewhirst WE, Manning HL. Propylene glycol toxicity associated with lorazepam infusion in a patient receiving continuous veno-venous hemofiltration with dialysis. Anesth Analg 2002 Jun; 94 (6): 1583-1585
83. Wilson KC, Reardon C, Theodore AC, et al. Propylene glycol toxicity: a severe iatrogenic illness in ICU patients receiving IV benzodiazepines: a case series and pro-spective, observational pilot study. Chest 2005 Sep; 128 (3): 1674-1681
84. Zar T, Yusufzai I, Sullivan A, et al. Acute kidney injury, hyperosmolality and metabolic acidosis associated with lorazepam. Nat Clin Pract Nephrol 2007 Sep; 3 (9): 515-520
85. Ganesh A, Audu P. Hyperosmolar, increased-anion-gap metabolic acidosis and hyperglycemia after etomidate in-fusion. J Clin Anesth 2008 Jun; 20 (4): 290-293
86. Levy ML, Aranda M, Zelman V, et al. Propylene glycol toxicity following continuous etomidate infusion for the control of refractory cerebral edema. Neurosurgery 1995 Aug; 37 (2): 363-9, discussion 369-371
87. Miller MA, Forni A, Yogaratnam D. Propylene glycolinduced lactic acidosis in a patient receiving continuous infusion pentobarbital. Ann Pharmacother 2008 Oct; 42 (10): 1502-1506
88. Demey HE, Daelemans RA, Verpooten GA, et al. Propylene glycol-induced side effects during intravenous nitro-glycerin therapy. Intensive Care Med 1988; 14 (3): 221-226
89. Ruddick JA. Toxicology, metabolism, and biochemistry of 1,2-propanediol. Toxicol Appl Pharmacol 1972 Jan; 21 (1): 102-111
90. Hayman M, Seidl EC, Ali M, et al. Acute tubular necrosis associated with propylene glycol from concomitant ad-ministration of intravenous lorazepam and trimethoprim-sulfamethoxazole. Pharmacotherapy 2003 Sep; 23 (9): 1190-1194
91. Reynolds HN, Teiken P, Regan ME, et al. Hyperlactatemia, increased osmolar gap, and renal dysfunction during continuous lorazepam infusion. Crit Care Med 2000 May; 28 (5): 1631-1634
92. Vanlersberghe C, Camu F. Propofol. Handb Exp Pharmacol 2008; (182): 227-252
93. Bonhomme V, Demoitie J, Schaub I, et al. Acid-base status and hemodynamic stability during propofol and sevoflurane-based anesthesia in patients undergoing un-complicated intracranial surgery. J Neurosurg Anesthe-siol 2009 Apr; 21 (2): 112-119
94. Cravens GT, Packer DL, Johnson ME. Incidence of propofol infusion syndrome during noninvasive radio-frequency ablation for atrial flutter or fibrillation. Anesthesiology 2007 Jun; 106 (6): 1134-1138
95. Fudickar A, Bein B, Tonner PH. Propofol infusion syndrome in anaesthesia and intensive care medicine. Curr Opin Anaesthesiol 2006 Aug; 19 (4): 404-410
96. Vasile B, Rasulo F, Candiani A, et al. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. Intensive Care Med 2003 Sep; 29 (9): 1417-1425
97. Bray RJ. Propofol infusion syndrome in children. Paediatr Anaesth 1998; 8 (6): 491-499
98. Wolf A, Weir P, Segar P, et al. Impaired fatty acid oxidation in propofol infusion syndrome. Lancet 2001 Feb 24; 357 (9256): 606-607
99. Veenith TV, Pearce A. A case of lactic acidosis complicating assessment and management of asthma. Int Arch Med 2008; 1 (1): 3-5
100. Stratakos G, Kalomenidis J, Routsi C, et al. Transient lactic acidosis as a side effect of inhaled salbutamol. Chest 2002 Jul; 122 (1): 385-386
101. Leventhal LJ, Kochar G, Feldman NH, et al. Lactic acidosis in theophylline overdose. Am J Emerg Med 1989 Jul; 7 (4): 417-418
102. Judge BS. Differentiating the causes of metabolic acidosis in the poisoned patient. Clin Lab Med 2006 Mar; 26 (1): 31-48, vii
103. Tobin AE, Pellizzer AM, Santamaria JD. Mechanisms by which systemic salbutamol increases ventilation. Respir-ology 2006 Mar; 11 (2): 182-187
104. Braden GL, Johnston SS, Germain MJ, et al. Lactic acidosis associated with the therapy of acute broncho-spasm. N Engl J Med 1985 Oct 3; 313 (14): 890-891
105. Richards SR, Chang FE, Stempel LE. Hyperlactacidemia associated with acute ritodrine infusion. Am J Obstet Gynecol 1983 May 1; 146 (1): 1-5
106. Eizadi-Mood N. Nalidixic acid overdose and metabolic acidosis [letter]. CJEM 2006 Mar; 8 (2): 78
107. Suganthi AR, Ramanan AS, Pandit N, et al. Severe metabolic acidosis in nalidixic acid overdosage. Indian Pediatr 1993 Aug; 30 (8): 1025-1026
108. Phillips PJ, Need AG, Thomas DW, et al. Nalidixic acid and lactic acidosis. Aust N Z J Med 1979 Dec; 9 (6): 694-696
109. Neale R, Reynolds TM, Saweirs W. Statin precipitated lactic acidosis? J Clin Pathol 2004 Sep; 57 (9): 989-990
110. Goli AK, Goli SA, Byrd Jr RP, et al. Simvastatin-induced lactic acidosis: a rare adverse reaction? Clin Pharmacol Ther 2002 Oct; 72 (4): 461-464
111. Coronado BE, Opal SM, Yoburn DC. Antibiotic-induced D-lactic acidosis. Ann Intern Med 1995 Jun 1; 122 (11): 839-842
112. Ayub A, Faloon WW, Heinig RE. Encephalopathy following jejunoileostomy. JAMA 1981 Aug 28; 246 (9): 970-973
113. Kitabchi AE, Umpierrez GE, Fisher JN, et al. Thirty years of personal experience in hyperglycemic crises: diabetic ketoacidosis and hyperglycemic hyperosmolar state. J Clin Endocrinol Metab 2008 May; 93 (5): 1541-1552
114. Wrenn KD, Slovis CM, Minion GE, et al. The syndrome of alcoholic ketoacidosis. Am J Med 1991 Aug; 91 (2): 119-128
115. Elisaf M, Merkouropoulos M, Tsianos EV, et al. Acid-base and electrolyte abnormalities in alcoholic patients. Miner Electrolyte Metab 1994; 20 (5): 274-281
116. Yanagawa Y, Sakamoto T, Okada Y. Six cases of sudden cardiac arrest in alcoholic ketoacidosis. Intern Med 2008; 47 (2): 113-117
117. Kreisberg RA, Owen WC, Siegal AM. Ethanol-induced hyperlacticacidemia: inhibition of lactate utilization. J Clin Invest 1971 Jan; 50 (1): 166-174
118. Izzedine H, Launay-Vacher V, Deybach C, et al. Druginduced diabetes mellitus. Expert Opin Drug Saf 2005 Nov; 4 (6): 1097-1109
119. Makhzoumi ZH, McLean LP, Lee JH, et al. Diabetic ketoacidosis associated with aripiprazole. Pharmaco-therapy 2008 Sep; 28 (9): 1198-1202
120. Koller EA, Weber J, Doraiswamy PM, et al. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry 2004 Jun; 65 (6): 857-863
121. Leslie DL, Rosenheck RA. Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medica-tions. Am J Psychiatry 2004 Sep; 161 (9): 1709-1711
122. Bobes J, Rejas J, Garcia-Garcia M, et al. Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. Schizophr Res 2003 Jul 1; 62 (1-2): 77-88
123. Ramaswamy K, Kozma CM, Nasrallah H. Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine. Drug Saf 2007; 30 (7): 589-599
124. Bottai T, Quintin P, Perrin E. Antipsychotics and the risk of diabetes: a general data review. Eur Psychiatry 2005 Dec; 20 Suppl. 4: S349-57
125. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs 2005; 19 Suppl. 1: 1-93
126. Bergman RN, Ader M. Atypical antipsychotics and glucose homeostasis. J Clin Psychiatry 2005 Apr; 66 (4): 504-514
127. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy 2002 Jul; 22 (7): 841-852
128. Koller E, Schneider B, Bennett K, et al. Clozapineassociated diabetes. Am J Med 2001 Dec 15; 111 (9): 716-723
129. McMartin KE, Ambre JJ, Tephly TR. Methanol poisoning in human subjects: role for formic acid accumulation in the metabolic acidosis. Am J Med 1980 Mar; 68 (3): 414-418
130. Fujita M, Tsuruta R, Wakatsuki J, et al. Methanol intoxication: differential diagnosis from anion gap-increased acidosis. Intern Med 2004 Aug; 43 (8): 750-754
131. Jacobsen D, Hewlett TP, Webb R, et al. Ethylene glycol intoxication: evaluation of kinetics and crystalluria. Am J Med 1988 Jan; 84 (1): 145-152
132. Soghoian S, Sinert R, Wiener SW, et al. Ethylene glycol toxicity presenting with non-anion gap metabolic acido-sis. Basic Clin Pharmacol Toxicol 2009 Jan; 104 (1): 22-26
133. Linter CM, Linter SP. Severe lactic acidosis following paraldehyde administration. Br J Psychiatry 1986 Nov; 149: 650-651
134. Gutman RA, Burnell JM. Paraldehyde acidosis. Am J Med 1967 Mar; 42 (3): 435-440
135. Pearlman BL, Gambhir R. Salicylate intoxication: a clinical review. Postgrad Med 2009 Jul; 121 (4): 162-168
136. Mokhlesi B, Leikin JB, Murray P, et al. Adult toxicology in critical care: part II. Specific poisonings. Chest 2003 Mar; 123 (3): 897-922
137. Temple AR. Acute and chronic effects of aspirin toxicity and their treatment. Arch Intern Med 1981 Feb 23; 141 (3 Spec No): 364-369
138. Tsimihodimos V, Psychogios N, Kakaidi V, et al. Salicylate-induced proximal tubular dysfunction. Am J Kidney Dis 2007 Sep; 50 (3): 463-467
139. Pai AB, Shepler BM. Comparison of sevelamer hydrochloride and sevelamer carbonate: risk of metabolic acidosis and clinical implications. Pharmacotherapy 2009 May; 29 (5): 554-561
140. Ramos R, Moreso F, Borras M, et al. Sevelamer hydrochloride in peritoneal dialysis patients: results of a multi-center cross-sectional study. Perit Dial Int 2007 Nov-Dec; 27 (6): 697-701
141. Carlisle EJ, Donnelly SM, Vasuvattakul S, et al. Gluesniffing and distal renal tubular acidosis: sticking to the facts. J Am Soc Nephrol 1991 Feb; 1 (8): 1019-1027
142. Relman AS, Shelburne PF, Talman A. Profound acidosis resulting from excessive ammonium chloride in previously healthy subjects: a study of two cases. N Engl J Med 1961 Apr 27; 264: 848-852
143. Perera PM, Kularathne K, Gawarammana IB. Laryngeal edema and metabolic acidosis after Omnicide ingestion. Clin Toxicol (Phila) 2008 Nov; 46 (9): 858-860
144. Zabrodski RM, Schnurr LP. Anion gap acidosis with hypoglycemia in acetaminophen toxicity. Ann Emerg Med 1984 Oct; 13 (10): 956-959
145. Humphreys BD, Forman JP, Zandi-Nejad K, et al. Acetaminophen-induced anion gap metabolic acidosis and 5-oxoprolinuria (pyroglutamic aciduria) acquired in hospital. Am J Kidney Dis 2005 Jul; 46 (1): 143-146
146. Pitt J. Association between paracetamol and pyroglutamic aciduria. Clin Chem 1990 Jan; 36 (1): 173-174
147. Fenves AZ, Kirkpatrick III HM, Patel VV, et al. Increased anion gap metabolic acidosis as a result of 5-oxoproline (pyroglutamic acid): a role for acetaminophen. Clin J Am Soc Nephrol 2006 May; 1 (3): 441-447
148. Pitt JJ, Hauser S. Transient 5-oxoprolinuria and high anion gap metabolic acidosis: clinical and biochemical findings in eleven subjects. Clin Chem 1998 Jul; 44 (7): 1497-1503
149. Ookhtens M, Kaplowitz N. Role of the liver in interorgan homeostasis of glutathione and cyst(e)ine. Semin Liver Dis 1998; 18 (4): 313-329 (Pubitemid 29011037)
150. Martensson J, Gustafsson J, Larsson A. A therapeutic trial with N-acetylcysteine in subjects with hereditary glu-tathione synthetase deficiency (5-oxoprolinuria). J Inherit Metab Dis 1989; 12 (2): 120-130
151. Croal BL, Glen AC, Kelly CJ, et al. Transient 5-oxoprolinuria (pyroglutamic aciduria) with systemic acido-sis in an adult receiving antibiotic therapy. Clin Chem 1998 Feb; 44 (2): 336-340
152. Bonham JR, Rattenbury JM, Meeks A, et al. Pyroglutamic aciduria from vigabatrin. Lancet 1989 Jun 24; 1 (8652): 1452-1453
153. Kortmann W, van Agtmael MA, van Diessen J, et al. 5-Oxoproline as a cause of high anion gap metabolic acidosis: an uncommon cause with common risk factors. Neth J Med 2008 Sep; 66 (8): 354-357
154. Fraley DS, Adler S, Bruns F, et al. Metabolic acidosis after hyperalimentation with casein hydrolysate: occurrence in a starved patient. Ann Intern Med 1978 Mar; 88 (3): 352-354
155. Tsai IC, Huang JW, Chu TS, et al. Factors associated with metabolic acidosis in patients receiving parenteral nutri-tion. Nephrology (Carlton) 2007 Feb; 12 (1): 3-7
156. McCarron DA, Elliott WC, Rose JS, et al. Severe mixed metabolic acidosis secondary to rhabdomyolysis. Am J Med 1979 Nov; 67 (5): 905-908
157. Bosch X, Poch E, Grau JM. Rhabdomyolysis and acute kidney injury. N Engl J Med 2009 Jul 2; 361 (1): 62-72
158. Insull Jr W. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J 2006 Mar; 99 (3): 257-273
159. Scheel Jr PJ, Whelton A, Rossiter K, et al. Cholestyramineinduced hyperchloremic metabolic acidosis. J Clin Phar-macol 1992 Jun; 32 (6): 536-538
160. Fan FS, Chow KM, Szeto CC, et al. Hyperchloraemic metabolic acidosis. Emerg Med J 2008 Sep; 25 (9): 613
161. Quigley R. Proximal renal tubular acidosis. J Nephrol 2006 Mar-Apr; 19 Suppl. 9: S41-5
162. Heller I, Halevy J, Cohen S, et al. Significant metabolic acidosis induced by acetazolamide: not a rare complica-tion. Arch Intern Med 1985 Oct; 145 (10): 1815-1817
163. Menon GJ, Vernon SA. Topical brinzolamide and metabolic acidosis. Br J Ophthalmol 2006 Feb; 90 (2): 247-248
164. Elinav E, Ackerman Z, Gottehrer NP, et al. Recurrent lifethreatening acidosis induced by acetazolamide in a patient with diabetic type IV renal tubular acidosis. Ann Emerg Med 2002 Aug; 40 (2): 259-260
165. Chapron DJ, Gomolin IH, Sweeney KR. Acetazolamide blood concentrations are excessive in the elderly: pro-pensity for acidosis and relationship to renal function. J Clin Pharmacol 1989 Apr; 29 (4): 348-353
166. De Marchi S, Cecchin E, Tesio F. Intraocular pressure changes during hemodialysis: prevention of excessive dialytic rise and development of severe metabolic acidosis following acetazolamide therapy. Ren Fail 1989; 11 (2-3): 117-124
167. Sporn A, Scothorn DM, Terry JE. Metabolic acidosis induced by acetazolamide. J Am Optom Assoc 1991 Dec; 62 (12): 934-937
168. Shiber JR. Severe non-anion gap metabolic acidosis induced by topiramate: a case report. J Emerg Med. Epub 2009 Feb 18
169. Garris SS, Oles KS. Impact of topiramate on serum bicarbonate concentrations in adults. Ann Pharmacother 2005 Mar; 39 (3): 424-426
170. Stohr W, Paulides M, Bielack S, et al. Ifosfamide-induced nephrotoxicity in 593 sarcoma patients: a report from the Late Effects Surveillance System. Pediatr Blood Cancer 2007 Apr; 48 (4): 447-452 (Pubitemid 46340112)
171. Rossi R, Pleyer J, Schafers P, et al. Development of ifosfamide-induced nephrotoxicity: prospective follow-up in 75 patients. Med Pediatr Oncol 1999 Mar; 32 (3): 177-182
172. Skinner R, Pearson AD, English MW, et al. Risk factors for ifosfamide nephrotoxicity in children. Lancet 1996 Aug 31; 348 (9027): 578-580
173. Benesic A, Schwerdt G, Freudinger R, et al. Chloroacetaldehyde as a sulfhydryl reagent: the role of critical thiol groups in ifosfamide nephropathy. Kidney Blood Press Res 2006; 29 (5): 280-293
174. Yaseen Z, Michoudet C, Baverel G, et al. In vivo mesna and amifostine do not prevent chloroacetaldehyde nephro-toxicity in vitro. Pediatr Nephrol 2008 Apr; 23 (4): 611-618
175. Alexandridis G, Liberopoulos E, Elisaf M. Aminoglycoside-induced reversible tubular dysfunction. Pharmaco-logy 2003 Mar; 67 (3): 118-120
176. Ashouri OS. Hyperkalemic distal renal tubular acidosis and selective aldosterone deficiency: combination in a patient with lead nephropathy. Arch Intern Med 1985 Jul; 145 (7): 1306-1307
177. Kobayashi E, Suwazono Y, Honda R, et al. Changes in renal tubular and glomerular functions and biological acid-base balance after soil replacement in Cd-polluted rice paddies calculated with a general linear mixed model. Biol Trace Elem Res 2008 Aug; 124 (2): 164-172
178. Husband P, McKellar WJ. Infantile renal tubular acidosis due to mercury poisoning. Arch Dis Child 1970 Apr; 45 (240): 264-268
179. Wegienka LC, Weller JM. Renal tubular acidosis caused by degraded tetracycline. Arch Intern Med 1964 Aug; 114: 232-235
180. Perry DJ, Weiss RB. Nephrotoxicity of streptozocin [letter]. Ann Intern Med 1982 Jan; 96 (1): 122
181. Peterson BA, Collins AJ, Vogelzang NJ, et al. 5-Azacytidine and renal tubular dysfunction. Blood 1981 Jan; 57 (1): 182-185
182. Butler Jr HE, Morgan JM, Smythe CM. Mercaptopurine and acquired tubular dysfunction in adult nephrosis. Arch Intern Med 1965 Dec; 116 (6): 853-856
183. Smith GC, Balfe JW, Kooh SW. Anticonvulsants as a cause of Fanconi syndrome. Nephrol Dial Transplant 1995; 10 (4): 543-545
184. Neelakantappa K, Gallo GR, Lowenstein J. Ranitidineassociated interstitial nephritis and Fanconi syndrome. Am J Kidney Dis 1993 Aug; 22 (2): 333-336
185. Garella S, Chang BS, Kahn SI. Dilution acidosis and contraction alkalosis: review of a concept. Kidney Int 1975 Nov; 8 (5): 279-283
186. Mittal MK, Florin T, Perrone J, et al. Toxicity from the use of niacin to beat urine drug screening. Ann Emerg Med 2007 Nov; 50 (5): 587-590
187. Earthman TP, Odom L, Mullins CA. Lactic acidosis associated with high-dose niacin therapy. South Med J 1991 Apr; 84 (4): 496-497
188. Schwab RA, Bachhuber BH. Delirium and lactic acidosis caused by ethanol and niacin coingestion. Am J Emerg Med 1991 Jul; 9 (4): 363-365